Skip to content

Advanced BioMedical Technologies, Inc.: 10-Q filed 2013-03-25

What Advanced BioMedical Technologies, Inc. reported in its quarterly report filed 2013-03-25 (fiscal Q1 2013): 21 published measures, 84 facts as tagged in accession 0001354488-13-001462.

This filing

Form
10-Q (quarterly report)
Filed
2013-03-25
Fiscal period
fiscal Q1 2013
Accession
0001354488-13-001462 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Advanced BioMedical Technologies, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-01-31203,733USD
At 2012-10-31214,012USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-01-312,604,013USD
At 2012-10-312,440,207USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-01-31-2,400,280USD
At 2012-10-31-2,226,195USD
At 2011-10-31-1,562,770USD
At 2010-10-31-1,490,497USD
At 2009-10-31-1,262,757USD
At 2008-10-31-750,424USD
At 2007-12-31-515,317USD
At 2006-12-31-330,066USD
At 2005-12-31-158,076USD
At 2004-12-31340,280USD
At 2003-12-31434,864USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-01-3144,488USD
At 2012-10-3149,092USD
At 2012-01-3172,668USD
At 2011-10-3178,781USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-11-01 to 2013-01-31-175,261USD92
2002-09-25 to 2013-01-31-3,857,269USD3782
2011-11-01 to 2012-10-31-758,525USD366
2011-11-01 to 2012-01-31-199,465USD92
2010-11-01 to 2011-10-31-487,439USD365
2009-11-01 to 2010-10-31-816,799USD365
2008-11-01 to 2009-10-31-558,432USD365
2008-01-01 to 2008-10-31-227,038USD305
2007-01-01 to 2007-12-31-196,871USD365
2006-01-01 to 2006-12-31-191,014USD365
2005-01-01 to 2005-12-31-511,233USD365
2004-01-01 to 2004-12-31-94,229USD366
2003-01-01 to 2003-12-31-57,633USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-11-01 to 2013-01-31-156,520USD92
2002-09-25 to 2013-01-31-2,815,341USD3782
2011-11-01 to 2012-01-31-129,324USD92

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-11-01 to 2013-01-311,523USD92
2002-09-25 to 2013-01-31445,873USD3782
2011-11-01 to 2012-01-3166,918USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-11-01 to 2013-01-31153,382USD92
2002-09-25 to 2013-01-313,528,875USD3782
2011-11-01 to 2012-01-31163,415USD92

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-11-01 to 2013-01-31-1,523USD92
2002-09-25 to 2013-01-31-447,548USD3782
2011-11-01 to 2012-01-31-40,439USD92

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-01-31137,097USD
At 2012-10-31141,613USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-01-3164,961USD
At 2012-10-3170,729USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-01-312,604,013USD
At 2012-10-312,440,207USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-11-01 to 2013-01-31134,960USD92
2002-09-25 to 2013-01-313,769,982USD3782
2011-11-01 to 2012-01-31173,318USD92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-11-01 to 2013-01-3119,411USD92
2002-09-25 to 2013-01-31276,094USD3782
2011-11-01 to 2012-01-3117,632USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-01-3156,474,850shares
At 2012-10-3156,474,850shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-01-311,677,921USD
At 2012-10-311,671,956USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2013-01-31-221,498USD
At 2012-10-31-215,042USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2012-11-01 to 2013-01-31-175,261USD92
2002-09-25 to 2013-01-31-4,074,474USD3782
2011-11-01 to 2012-01-31-199,465USD92

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2012-11-01 to 2013-01-31-181,717USD92
2002-09-25 to 2013-01-31-4,078,767USD3782
2011-11-01 to 2012-10-31-794,606USD366
2011-11-01 to 2012-01-31-211,346USD92
2010-11-01 to 2011-10-31-553,291USD365
2009-11-01 to 2010-10-31-845,862USD365
2008-11-01 to 2009-10-31-560,288USD365
2008-01-01 to 2008-10-31-262,871USD305
2007-01-01 to 2007-12-31-224,272USD365
2006-01-01 to 2006-12-31-199,174USD365
2005-01-01 to 2005-12-31-521,459USD365
2004-01-01 to 2004-12-31-94,584USD366
2003-01-01 to 2003-12-31-57,848USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-11-01 to 2013-01-31109,111USD92
2002-09-25 to 2013-01-313,196,816USD3782
2011-11-01 to 2012-01-31150,380USD92

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-11-01 to 2013-01-316,438USD92
2002-09-25 to 2013-01-31297,072USD3782
2011-11-01 to 2012-01-315,306USD92

Inspect the source

Entity
Advanced BioMedical Technologies, Inc. / CIK 0001385799
Captured
SEC response SHA-256
1591f8b0cfab5a80255c1912235608d48fec8b1551b4e091e75b1bc63071e992

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385799.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))